Efficacy and safety of MCLA-129, an EGFR/c-MET bispecific antibody, in advanced non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Wang, Jie
Zhong, Jia
Wu, Lin
Chen, Bolin
Wang, Zhe-Hai
Yao, Yu
Dong, Xiaorong
Li, Wei
Ren, Xiubao
Hou, Xiaoming
Zang, Ai-min
Qu, Xiujuan
Zhang, Guojun
Wang, Yongsheng
Bai, Yuansong
Liu, Linlin
Yu, Guohua
Chen, Xingwu
Ding, Lieming
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Dept Med Oncol, Natl Canc Ctr, Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China
[2] Hunan Canc Hosp, Changsha, Peoples R China
[3] Cent South Univ, Xiangya Sch Med, Thorac Med Dept 2, Affiliated Canc Hosp, Changsha, Peoples R China
[4] Cent South Univ, Hunan Canc Hosp, Changsha, Peoples R China
[5] Shandong Canc Hosp & Inst, Jinan, Peoples R China
[6] Xi An Jiao Tong Univ, Affiliated Hosp 1, Xian, Peoples R China
[7] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Wuhan, Peoples R China
[8] Bengbu Med Coll, Affiliated Hosp 1, Bengbu, Peoples R China
[9] Tianjin Canc Inst & Hosp, Tianjin, Peoples R China
[10] Lanzhou Univ, Dept Med Oncol, Hosp 1, Lanzhou, Peoples R China
[11] Hebei Univ, Affiliated Hosp, Baoding, Peoples R China
[12] China Med Univ, Dept Med Oncol, Hosp 1, Shenyang, Peoples R China
[13] Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Peoples R China
[14] Sichuan Univ, West China Hosp, Chengdu, Peoples R China
[15] Jilin Univ, Dept Hematol & Oncol, China Japan Union Hosp, Changchun, Peoples R China
[16] Jilin Univ, China Japan Union Hosp, Changchun, Peoples R China
[17] Weifang Peoples Hosp, Weifang, Shandong, Peoples R China
[18] Yijishan Hosp, Affiliated Hosp 1, Wannan Med Coll, Wuhu, Peoples R China
[19] Betta Pharmaceut Co Ltd, Hangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8604
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Evaluation of c-Met FISH on Non-Small Cell Lung Cancer Samples with Known EGFR Mutational Status
    Bloom, K. J.
    Ha, T.
    Uyeda, L.
    Choppa, P.
    MODERN PATHOLOGY, 2012, 25 : 473A - 473A
  • [22] Evaluation of c-Met FISH on Non-Small Cell Lung Cancer Samples with Known EGFR Mutational Status
    Bloom, K. J.
    Uyeda, L.
    Choppa, P.
    LABORATORY INVESTIGATION, 2012, 92 : 473A - 473A
  • [23] JNJ-61186372 (JNJ-372), an EGFR-cMet bispecific antibody, in EGFR-driven advanced non-small cell lung cancer (NSCLC).
    Haura, Eric B.
    Cho, Byoung Chul
    Lee, Jong Seok
    Han, Ji-Youn
    Lee, Ki Hyeong
    Sanborn, Rachel E.
    Govindan, Ramaswamy
    Cho, Eun Kyung
    Kim, Sang-We
    Reckamp, Karen L.
    Sabari, Joshua K.
    Thayu, Meena
    Bae, Kyounghwa
    Knoblauch, Roland Elmar
    Curtin, Joshua
    Haddish-Berhane, Nahor
    Sherman, Laurie Jill
    Lorenzi, Matthew V.
    Park, Keunchil
    Bauml, Joshua
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [24] A phase I study of CKD-702, an EGFR-cMET bispecific antibody, in advanced or metastatic non-small cell lung cancer (NSCLC)
    Kim, D-W.
    Lee, S-H.
    Jang, I-J.
    Park, K-J.
    Lee, D. H.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1010 - S1010
  • [25] JNJ-61186372, an EGFRcMet bispecific antibody, in EGFR Exon 20 insertion-driven advanced non-small cell lung cancer (NSCLC)
    Yun, Jiyeon
    Kang, Han Na
    Lee, Soo-Hwan
    Jeong, Seo-Yoon
    Park, Chae Won
    Kim, Jae-Hwan
    Pyo, Kyoung-Ho
    Lee, Ji Min
    Kim, Seok-Young
    Hong, Min Hee
    Kim, Hye Ryun
    Thayu, Meena
    Curtin, Joshua
    Knoblauch, Roland
    Lorenzi, Matthew
    Cho, Byoung Chul
    CANCER RESEARCH, 2020, 80 (16)
  • [26] A phase I/II study of REGN5093, a MET x MET bispecific antibody, in patients with MET-altered advanced non-small cell lung cancer (NSCLC).
    Rowlands, Tracey
    Boyapati, Anita
    Li, Siyu
    Daly, Christopher
    Seebach, Frank A.
    Lowy, Israel
    Rietschel, Petra
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [27] Efficacy and safety of crizotinib in patients (pts) with advanced MET exon 14-altered non-small cell lung cancer (NSCLC).
    Drilon, Alexander E.
    Camidge, D. Ross
    Ou, Sai-Hong Ignatius
    Clark, Jeffrey William
    Socinski, Mark A.
    Weiss, Jared
    Riely, Gregory J.
    Winter, Maria
    Wang, Sherry C.
    Monti, Katherine
    Wilner, Keith D.
    Paik, Paul K.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [28] Efficacy and safety of bevacizumab in the treatment of advanced, non-squamous non-small cell lung cancer (NSCLC)
    Tassinari, D.
    Drudi, F.
    Carloni, F.
    Nicoletti, S.
    Possenti, C.
    Santelmo, C.
    Lazzari, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [29] Safety and efficacy of dostarlimab in patients (pts) with recurrent/advanced non-small cell lung cancer (NSCLC)
    Subramanian, J.
    Moreno, V.
    Bosch-Barrera, J.
    Pikiel, J.
    Kristeleit, R.
    Guo, W.
    Danaee, H.
    Im, E.
    Roda, D.
    ANNALS OF ONCOLOGY, 2020, 31 : S886 - S887
  • [30] Telisotuzumab vedotin (Teliso-V) in combination with osimertinib in patients with advanced EGFR-mutated, c-met overexpressing, non-small cell lung cancer (NSCLC): Safety and efficacy results from phase Ib study
    Horinouchi, H.
    Goldman, J. W.
    Cho, B. C.
    Tomasini, P.
    Dunbar, M.
    Hoffman, D.
    Parikh, A.
    Blot, V.
    Camidge, D. R.
    ANNALS OF ONCOLOGY, 2022, 33 : S1592 - S1592
12345